Study of immune medicines plus pills for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests how safe and active a combination of antibody medicines and oral pills is for adults with certain relapsed B-cell non-Hodgkin lymphoma that lights up on PET scans. The goal is to find a dosing plan and see if the treatment can shrink lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your performance status is 0, 1, or 2 (you can still do daily activities with some limits).
- Your lymphoma diagnosis is a type that typically has a target called CD20, confirmed by pathology (and you can provide tumor tissue/pathology paperwork).
- Your lymphoma shows up on PET as active (PET-positive) and you have measurable tumor areas on CT/PET.
- You have adequate blood counts and generally normal lab results, without needing growth factors or recent blood transfusions in the 14 days before the first dose.
- You can safely prevent pregnancy during treatment and for a set time after the last dose (and you will follow the required contraception/abstinence rules).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
This trial tests a combination of two drugs, Mosunetuzumab and Tislelizumab, for people with relapsed or refractory follicular lymphoma. The goal is to see if this combination can help when at least two prior treatments have stopped working.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.